Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on January 11, 2021, to disclose that it had posted an investor presentation to its website on January 10, 2021. This presentation, attached as Exhibit 99.1 to the filing, is intended to provide investors with updated information regarding the company's business and strategic outlook. While the content of the presentation is not directly incorporated into the SEC filing for liability purposes, its availability signifies ongoing communication with the investment community. Investors are encouraged to review the presentation for insights into the company's performance, pipeline, and future growth strategies. The primary purpose of this 8-K filing is to make the investor presentation publicly accessible, adhering to Regulation FD. This indicates that the information contained within the presentation is considered material by the company and is being shared broadly. Investors should consider this presentation as a key source of recent management commentary and forward-looking statements, though they should also be mindful that such information is not subject to the same rigorous review as formally filed financial statements.
Key Highlights
- 1BMY filed an 8-K on January 11, 2021, to announce the posting of an investor presentation.
- 2The investor presentation was made available on the company's website on January 10, 2021.
- 3The presentation is attached as Exhibit 99.1 to the 8-K filing.
- 4The filing is made under Regulation FD disclosure rules.
- 5Information in the presentation is not deemed 'filed' for Section 18 of the Exchange Act, limiting liability.
- 6The company is providing updated information to investors through this presentation.
- 7Investors should consult the presentation for current company insights and outlook.